New N - and O -arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT 7 and 5-HT 1A receptor ligands: Synthesis, structure-activity relationships, and molecular modeling studies-Reference-Cited by-同舟云学术

New N - and O -arylpiperazinylalkyl pyrimidines and 2-methylquinazolines derivatives as 5-HT 7 and 5-HT 1A receptor ligands: Synthesis, structure-activity relationships, and molecular modeling studies

Published:2017-02 Issue:3 Volume:25 Page:1250-1259
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Intagliata Sebastiano^ORCID,Modica Maria N.,Pittalà Valeria,Salerno Loredana,Siracusa Maria A.,Cagnotto Alfredo,Salmona Mario,Kurczab Rafał,Romeo Giuseppe

Funder

Italian MIUR

University of Catania

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference49 articles.

1. Quinazoline alkaloids in nature

2. Selective copper(II) acetate and potassium iodide catalyzed oxidation of aminals to dihydroquinazoline and quinazolinone alkaloids

3. Pharmacological Effects of Rutaecarpine, an Alkaloid Isolated from Evodia rutaecarpa

4. Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Halogen Bonding Hot Spots as a Constraint in Virtual Screening: A Case Study of 5-HT₇R;Journal of Medicinal Chemistry;2024-07-31

2. Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands;Medicinal Research Reviews;2024-05-29

3. New acetamide derivatives of quinazoline-2,4(1H,3H)-dione: neural network prediction, synthesis, and psychotropic activity;Russian Chemical Bulletin;2023-04

4. A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands;Current Medicinal Chemistry;2022-09

5. Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use;International Journal of Molecular Sciences;2022-01-06